Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. CYBN, LYEL, TIL, CRDF, LFVN, RAPT, DERM, ACRS, SLS, and PBYIShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Cybin (CYBN), Lyell Immunopharma (LYEL), Instil Bio (TIL), Cardiff Oncology (CRDF), Lifevantage (LFVN), Rapt Therapeutics (RAPT), Journey Medical (DERM), Aclaris Therapeutics (ACRS), SELLAS Life Sciences Group (SLS), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Cybin Lyell Immunopharma Instil Bio Cardiff Oncology Lifevantage Rapt Therapeutics Journey Medical Aclaris Therapeutics SELLAS Life Sciences Group Puma Biotechnology Nabriva Therapeutics (NASDAQ:NBRV) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Does the media prefer NBRV or CYBN? In the previous week, Cybin had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Cybin and 0 mentions for Nabriva Therapeutics. Cybin's average media sentiment score of 0.24 beat Nabriva Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the news media. Company Overall Sentiment Nabriva Therapeutics Neutral Cybin Neutral Which has more volatility and risk, NBRV or CYBN? Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Is NBRV or CYBN more profitable? Cybin has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Cybin's return on equity of -37.58% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Cybin N/A -37.58%-36.59% Do analysts rate NBRV or CYBN? Cybin has a consensus target price of $85.00, suggesting a potential upside of 1,085.50%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals & insiders hold more shares of NBRV or CYBN? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, NBRV or CYBN? Nabriva Therapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ACybinN/AN/A-$57.88M-$3.88-1.85 SummaryCybin beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$791.77M$5.62B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E Ratio0.001.1830.2925.74Price / SalesN/A26.06463.41115.83Price / CashN/A19.5638.2159.48Price / BookN/A6.588.826.15Net Income-$57.19M-$4.98M$3.25B$265.06M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070CYBNCybin2.6131 of 5 stars$7.55-1.8%$85.00+1,026.6%N/A$178.22MN/A-1.7250News CoveragePositive NewsLYELLyell Immunopharma3.3013 of 5 stars$11.60+2.0%$15.00+29.4%-60.5%$177.95M$60K-0.46270Trending NewsEarnings ReportGap DownTILInstil Bio3.0994 of 5 stars$26.78+8.2%$119.00+344.4%+160.6%$177.02MN/A-2.25410News CoverageEarnings ReportGap DownCRDFCardiff Oncology2.0472 of 5 stars$2.57+2.2%$11.70+356.1%+8.9%$171.32M$680K-2.9620LFVNLifevantage4.2195 of 5 stars$13.40+0.8%$30.50+127.6%+79.6%$168.59M$200.16M19.41260News CoverageRAPTRapt Therapeutics4.5879 of 5 stars$10.10-6.1%$20.57+103.7%-46.4%$167.82M$1.53M-0.5380Earnings ReportAnalyst ForecastAnalyst RevisionDERMJourney Medical1.881 of 5 stars$7.19+0.6%$9.50+32.2%+50.4%$167.67M$56.13M-18.4590News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionACRSAclaris Therapeutics2.6239 of 5 stars$1.56-0.3%$8.71+460.4%+42.9%$167.29M$18.72M-1.11100Earnings ReportSLSSELLAS Life Sciences Group2.8757 of 5 stars$1.62+1.6%$7.00+333.4%+29.8%$160.15M$1M-4.2210News CoverageEarnings ReportPBYIPuma Biotechnology4.1339 of 5 stars$3.23+1.5%$7.00+116.9%+46.8%$160.11M$230.50M4.19200Gap Down Related Companies and Tools Related Companies CYBN Alternatives LYEL Alternatives TIL Alternatives CRDF Alternatives LFVN Alternatives RAPT Alternatives DERM Alternatives ACRS Alternatives SLS Alternatives PBYI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access